Table 5. Type-specific relative rates (RRs) and Population Attributable Fractions (PAFs) of referral to colposcopy and histologically confirmed cervical lesions by the most important HPV types.

	Colposcopy indicated		CIN 2+		CIN 3+
Type(s)	RRa (95% CI)	PAF (95% CI)	RRa (95% CI)	PAF (95% CI)	RRa (95% CI)	PAF
HPV 16	3.27 (2.59–4.11)	19.5% (14.4–24.3)	7.27 (5.23–10.10)	40.3% (31.1–48.2)	13.5 (7.75–23.4)	55.8% (40.0–67.5)
HPV 18	1.66 (1.09–2.53)	2.4% (0–4.8)	1.51 (0.73–3.12)	1.6% (0–4.9%)	1.26 (0.30–5.25)	0.7% (0–5.0)
HPV 31	1.98 (1.47–2.66)	6.6% (2.9–10.1)	3.02 (2.03–4.50)	12.8% (6.1–19.1)	2.04 (0.96–4.36)	6.5% (0–14.9)
HPV 52	1.03 (0.66–1.60)	0.1% (0–2.4%)	1.47 (0.80–2.68)	2.3% (0–6.4)	1.92 (0.74–4.96)	3.8% (0–10.6)
Group 1/2Ab	3.15 (2.44–4.05)	54.5% (44.5–62.7)	4.71 (2.98–7.44)	68.4% (53.2–78.7)	7.45 (3.17–17.5)	78.3% (53.4–89.9)
Group 2Bc	1.50 (1.15–1.96)	5.9% (1.5–10.1)	0.86 (0.51–1.44)	NA	0.75 (0.30–1.90)	NA
Group 3d	1.15 (0.82–1.61)	1.3% (0–4.5)	0.43 (0.20–0.93)	NA	NA	NA
Any HPVe	3.95 (2.82–5.53)	67.6% (56.1–76.0)	3.60 (2.18–5.96)	64.9% (44.8–77.6)	5.11% (2.04–12.8)	74.0% (39.7–88.8)

Abbreviation: NA=not applicable.

^aAssociation between type-specific infection and outcome by Poisson regression. Type-specific RRs adjusted for age and for coinfection with all single Group 1/2A HPV types and pooled Group 2B and Group 3 HPV types, unless otherwise specified.

^bInfection with one or more Group 1/2A HPV type (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68), coinfection with HPV types of Group 2B and / or Group 3 allowed. Adjusted for age and Group 2B and Group 3 HPV types.

^cInfection with one or more Group 2B HPV type (26, 30, 53, 66, 67, 69, 70, 73 and 82), coinfection with HPV types of Group 3 allowed.

^dInfection with one or more Group 3 HPV type (6, 7, 9, 11, 40, 42, 43, 61, 74, 81, 83, 86, 87, 89, 90, 91 and 114).

^eInfection with one or more HPV of any type. Adjusted for age.